A New Animal Model of Insulin-Glucose Dynamics in the Intraperitoneal Space Enhances Closed-Loop Control Performance.

Current artificial pancreas systems (AP) operate via subcutaneous (SC) glucose sensing and SC insulin delivery. Due to slow diffusion and transport dynamics across the interstitial space, even the most sophisticated control algorithms in on-body AP systems cannot react fast enough to maintain tight glycemic control under the effect of exogenous glucose disturbances caused by ingesting meals or performing physical activity. Recent efforts made towards the development of an implantable AP have explored the utility of insulin infusion in the intraperitoneal (IP) space: a region within the abdominal cavity where the insulin-glucose kinetics are observed to be much more rapid than the SC space. In this paper, a series of canine experiments are used to determine the dynamic association between IP insulin boluses and plasma glucose levels. Data from these experiments are employed to construct a new mathematical model and to formulate a closed-loop control strategy to be deployed on an implantable AP. The potential of the proposed controller is demonstrated via in-silico experiments on an FDA-accepted benchmark cohort: the proposed design significantly outperforms a previous controller designed using artificial data (time in clinically acceptable glucose range: 97.3±1.5% vs. 90.1±5.6%). Furthermore, the robustness of the proposed closed-loop system to delays and noise in the measurement signal (for example, when glucose is sensed subcutaneously) and deleterious glycemic changes (such as sudden glucose decline due to physical activity) is investigated. The proposed model based on experimental canine data leads to the generation of more effective control algorithms and is a promising step towards fully automated and implantable artificial pancreas systems.

[1]  G. Steil,et al.  Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era , 2015, Diabetes Care.

[2]  E. Renard,et al.  Implantable insulin pumps: an effective option with restricted dissemination. , 2014, The lancet. Diabetes & endocrinology.

[3]  R. E. Carlson,et al.  Monotone Piecewise Cubic Interpolation , 1980 .

[4]  Eric Renard,et al.  Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. , 2010, Diabetes technology & therapeutics.

[5]  C. Cobelli,et al.  In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.

[6]  Eric Renard,et al.  A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients. , 2011, Diabetes Technology & Therapeutics.

[7]  Hui-yu Liu,et al.  Insulin Is a Stronger Inducer of Insulin Resistance than Hyperglycemia in Mice with Type 1 Diabetes Mellitus (T1DM)* , 2009, The Journal of Biological Chemistry.

[8]  D. Edgerton,et al.  Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 Diabetes , 2015, Diabetes.

[9]  Lauren M. Huyett,et al.  Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms , 2014, Diabetes Care.

[10]  S. Colberg,et al.  Pumping Insulin During Exercise , 2002, The Physician and sportsmedicine.

[11]  W. Blackard,et al.  Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. , 1975, The Journal of clinical investigation.

[12]  S. Yen,et al.  Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. , 1974, The New England journal of medicine.

[13]  Eyal Dassau,et al.  Event-Triggered Model Predictive Control for Embedded Artificial Pancreas Systems , 2018, IEEE Transactions on Biomedical Engineering.

[14]  Ahmad Haidar,et al.  The Artificial Pancreas: How Closed-Loop Control Is Revolutionizing Diabetes , 2016, IEEE Control Systems.

[15]  M. Matsuda,et al.  Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man , 1994, Diabetologia.

[16]  L. Kvols,et al.  Distribution of somatostatin receptors in normal and tumor tissue. , 1990, Metabolism: clinical and experimental.

[17]  Timothy J. Garrett,et al.  Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes , 2017, Scientific Reports.

[18]  G. Steil,et al.  Evaluation of the Effect of Gain on the Meal Response of an Automated Closed-Loop Insulin Delivery System , 2006, Diabetes.

[19]  R. Gans,et al.  Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia , 2014, Clinical endocrinology.

[20]  Cesar C. Palerm,et al.  Physiologic insulin delivery with insulin feedback: A control systems perspective , 2011, Comput. Methods Programs Biomed..

[21]  E. Renard,et al.  A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion , 2009, Diabetes, obesity & metabolism.

[22]  A BuckinghamBruce,et al.  Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents with Type 1 Diabetes at Diabetes Camp. , 2016 .

[23]  H Gin,et al.  Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. , 2003, Diabetes & metabolism.

[24]  Garry M. Steil,et al.  Automated insulin delivery for type 1 diabetes , 2006 .

[25]  C. J. Goodner,et al.  Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas , 1974, Science.

[26]  C Jaffiol,et al.  Insulin Underdelivery From Implanted Pumps Using Peritoneal Route: Determinant role of insulin pump compatibility , 1996, Diabetes Care.

[27]  Complications of the Pump Pocket May Represent a Significant Cause of Incidents With Implanted Systems for Intraperitoneal Insulin Delivery , 1994, Diabetes Care.

[28]  Stuart A Weinzimer,et al.  Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover Study , 2012, Journal of diabetes science and technology.

[29]  Dale E. Seborg,et al.  Control-Relevant Models for Glucose Control Using A Priori Patient Characteristics , 2012, IEEE Transactions on Biomedical Engineering.

[30]  A. Cherrington,et al.  Intraportal glucose delivery enhances the effects of hepatic glucose load on net hepatic glucose uptake in vivo. , 1991, The Journal of clinical investigation.

[31]  Eyal Dassau,et al.  Design and in silico evaluation of an intraperitoneal-subcutaneous (IP-SC) artificial pancreas , 2014, Comput. Chem. Eng..

[32]  R. Hovorka Continuous glucose monitoring and closed‐loop systems , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[33]  G. Skjåk‐Braek,et al.  SUCCESSFUL REVERSAL OF SPONTANEOUS DIABETES IN DOGS BY INTRAPERITONEAL MICROENCAPSULATED ISLETS , 1992, Transplantation.

[34]  E Renard,et al.  Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. , 2006, Diabetes & metabolism.

[35]  L. Laffel,et al.  Impact of Carbohydrate Counting on Glycemic Control in Children With Type 1 Diabetes , 2009, Diabetes Care.

[36]  C Cobelli,et al.  Compartmental modeling of glucagon kinetics in the conscious dog. , 1995, Metabolism: clinical and experimental.

[37]  M. Morari,et al.  Internal model control: PID controller design , 1986 .

[38]  A. Cherrington,et al.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. , 1999, Diabetes.

[39]  Eyal Dassau,et al.  Design and Evaluation of a Robust PID Controller for a Fully Implantable Artificial Pancreas , 2015, Industrial & engineering chemistry research.

[40]  Thomas F. Edgar,et al.  Process Dynamics and Control , 1989 .

[41]  R. Gans,et al.  Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes. , 2016, The Journal of clinical endocrinology and metabolism.

[42]  R. Gans,et al.  Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability. , 2015, Diabetes technology & therapeutics.

[43]  J Hans DeVries,et al.  Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. , 2014, Diabetes technology & therapeutics.

[44]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[45]  Jennings,et al.  The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. , 1976, The Journal of clinical investigation.

[46]  D. Cuthbertson,et al.  Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome , 2012, BMC Veterinary Research.

[47]  D. Goldstein,et al.  Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. , 2002, Diabetes care.

[48]  G. Pozza,et al.  Intraperitoneal Insulin Absorption After Lona-Term Intraperitoneal Insulin Therapy , 1995, Diabetes Care.

[49]  Eyal Dassau,et al.  Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control‐based fully‐automated artificial pancreas in patients with type 1 diabetes: a pilot study , 2017, Diabetes, obesity & metabolism.

[50]  Eyal Dassau,et al.  Embedded Control in Wearable Medical Devices: Application to the Artificial Pancreas , 2016 .

[51]  C. C. Palerm,et al.  Closed-Loop Insulin Delivery Using a Subcutaneous Glucose Sensor and Intraperitoneal Insulin Delivery , 2009, Diabetes Care.

[52]  Lauren M. Huyett,et al.  Glucose Sensing in the Peritoneal Space Offers Faster Kinetics Than Sensing in the Subcutaneous Space , 2014, Diabetes.

[53]  M. Hanefeld,et al.  Postprandial glucose regulation and diabetic complications. , 2004, Archives of internal medicine.

[54]  A. Fougner,et al.  Intraperitoneal Glucose Sensing is Sometimes Surprisingly Rapid , 2016 .

[55]  E. Araki,et al.  Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas , 2003, Journal of Artificial Organs.

[56]  R. Eaton,et al.  Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. , 1983, The Journal of clinical endocrinology and metabolism.